FDA approves Mirum’s drug for ultra-rare soft tissue disease
The FDA has approved the third treatment for a debilitating genetic disease that turns muscle and connective tissue to bone. Mirum Pharmaceuticals’ zilurgisertib, which blocks the ALK2 receptor, will be marketed as Atebrioz for patients ...
We haven't written up this one. Endpoints News has the full story — the link below goes straight to it.